DAWN Logo

Day One Biopharmaceuticals, Inc. (DAWN) 

NASDAQ
Market Cap
$1.37B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
646 of 968
Rank in Industry
361 of 556

Largest Insider Buys in Sector

DAWN Stock Price History Chart

DAWN Stock Performance

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Insider Activity of Day One Biopharmaceuticals, Inc.

Over the last 12 months, insiders at Day One Biopharmaceuticals, Inc. have bought $0 and sold $6.67M worth of Day One Biopharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Day One Biopharmaceuticals, Inc. have bought $34.92M and sold $17.97M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 111,387 shares for transaction amount of $1.11M was made by AI Day1 LLC (10 percent owner) on 2023‑10‑20.

List of Insider Buy and Sell Transactions, Day One Biopharmaceuticals, Inc.

2024-11-18SaleHEAD OF R&D
2,206
0.0022%
$13.21$29,142+2.61%
2024-11-18SaleCOO, CFO AND SECRETARY
2,602
0.0026%
$13.21$34,373+2.61%
2024-11-18SaleCHIEF EXECUTIVE OFFICER
10,554
0.0106%
$13.21$139,420+2.61%
2024-11-18SaleGENERAL COUNSEL
3,165
0.0032%
$13.21$41,810+2.61%
2024-11-11SaleHEAD OF R&D
10,000
0.01%
$16.10$160,994-13.49%
2024-11-08SaleHEAD OF R&D
18,255
0.0176%
$16.17$295,229-16.29%
2024-11-07SaleHEAD OF R&D
11,245
0.0113%
$16.03$180,287-12.94%
2024-10-31SaleHEAD OF R&D
500
0.0006%
$16.02$8,010-5.37%
2024-09-10SaleHEAD OF R&D
30,000
0.0339%
$14.22$426,675-1.67%
2024-08-16SaleHEAD OF R&D
2,232
0.0027%
$14.00$31,2460.00%
2024-08-16SaleCOO, CFO AND SECRETARY
2,633
0.0031%
$14.00$36,8600.00%
2024-08-16SaleCHIEF EXECUTIVE OFFICER
10,681
0.0127%
$14.00$149,5240.00%
2024-08-16SaleGENERAL COUNSEL
3,202
0.0038%
$14.00$44,8250.00%
2024-07-16SaleHEAD OF R&D
20,000
0.0273%
$16.01$320,226-11.99%
2024-06-21Saledirector
10,000
0.012%
$13.19$131,877+2.96%
2024-06-10SaleHEAD OF R&D
30,000
0.0347%
$12.62$378,588+11.81%
2024-05-16SaleHEAD OF R&D
2,267
0.0026%
$16.08$36,450-13.23%
2024-05-16SaleCHIEF EXECUTIVE OFFICER
7,873
0.009%
$16.08$126,588-13.23%
2024-05-16SaleCOO, CFO AND SECRETARY
2,675
0.0031%
$16.08$43,011-13.23%
2024-05-16SaleGENERAL COUNSEL
3,253
0.0037%
$16.08$52,304-13.23%

Insider Historical Profitability

5.29%
Blackman Samuel C.HEAD OF R&D
1064015
1.0551%
$13.62035
York Charles N IICOO, CFO AND SECRETARY
240133
0.2381%
$13.62024
Bender JeremyCHIEF EXECUTIVE OFFICER
108377
0.1075%
$13.62024
Ramasastry Sairadirector
40485
0.0401%
$13.6201
Dubow AdamGENERAL COUNSEL
32162
0.0319%
$13.6205
AI Day1 LLC10 percent owner
12929322
12.8209%
$13.6280+13.88%
Blavatnik Len
10684638
10.595%
$13.6210+23.65%
Canaan XI L.P.10 percent owner
8464301
8.3933%
$13.6217<0.0001%
TAKEDA PHARMACEUTICAL CO LTD10 percent owner
6120124
6.0688%
$13.6204
Atlas Venture Associates Opportunity I, LLC
766667
0.7602%
$13.6210+23.65%
Gladstone Michael
766667
0.7602%
$13.6210+23.65%
Atlas Venture Fund XI, L.P.10 percent owner
741396
0.7352%
$13.6220<0.0001%
Grant Julie Papanekdirector
330000
0.3272%
$13.62124<0.0001%
Josey John A.director
72292
0.0717%
$13.6210<0.0001%
Becker Daniel J.director
5000
0.005%
$13.6210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$129.02M8.947.81M0%+$00.13
Atlas Venture Life Science Advisors Llc$106.23M7.366.43M-15.48%-$19.46M9.86
BlackRock$83.12M5.765.03M-1.85%-$1.56M<0.01
The Vanguard Group$78.87M5.464.77M+0.1%+$78,255.24<0.01
Fidelity Investments$72.76M5.044.4M+10.99%+$7.21M0.01
Franklin Templeton Investments$62.89M4.363.81M-10.15%-$7.1M0.02
State Street$47.82M3.312.89M-14.36%-$8.02M<0.01
Viking Global Investors$42.27M2.932.56M0%+$00.02
T. Rowe Price$37.99M2.632.3M-0.73%-$280,846.640.01
Braidwell Lp$35.91M2.492.17M-48.44%-$33.73M2.04
Goldman Sachs$35.31M2.452.14M+0.88%+$307,965.840.01
Janus Henderson$33.57M2.332.03M+19.83%+$5.56M0.02
Deerfield Management$29.16M2.021.77M+0.23%+$68,293.680.07
TimesSquare Capital Management LLC$27.01M1.871.64M-1.86%-$510,806.050.4
Geode Capital Management$22.75M1.581.38M+2.09%+$464,972.27<0.01
Maverick Capital Ltd$20.76M1.441.26MNew+$20.76M0.4
Boxer Capital, LLC$19.66M1.361.19M0%+$00.4
Polar Capital$19.58M1.361.19M-14.44%-$3.3M0.11
Dimensional Fund Advisors$16.22M1.12981,572+26.18%+$3.36M<0.01
Driehaus Capital Management LLC$11.88M0.82719,011+48.79%+$3.89M0.12
Parkman Healthcare Partners Llc$11.43M0.79691,812+10.56%+$1.09M1.42
DAFNA Capital Management, LLC$11.01M0.76666,463-2.91%-$330,400.010.27
Northern Trust$9.22M0.64558,145-3.23%-$307,387.63<0.01
Sphera Fund$8.14M0.56492,627-3.97%-$336,561.960.05
Charles Schwab$7.56M0.52457,652+1.04%+$77,941.36<0.01
Nicholas Investment Partners, L.P.$5.98M0.41361,767+19.27%+$965,577.510.68
PFM Health Sciences$5.87M0.41355,251-72.75%-$15.67M0.16
Candriam S C A$4.79M0.33290,0140%+$00.03
Woodline Partners LP$4.5M0.31272,5380%+$00.04
Wellington Management Company$4.5M0.31272,117+30.22%+$1.04M<0.01
Schonfeld Group$3.93M0.27237,748+32.87%+$971,607.040.02
Morgan Stanley$3.84M0.27232,550-30.47%-$1.68M<0.0001
D. E. Shaw & Co.$3.7M0.26224,219+14.7%+$474,619.61<0.01
BNY Mellon$3.56M0.25215,383-8.03%-$310,823.87<0.01
Samsara Biocapital Llc$3.24M0.23196,4250%+$00.51
Rafferty Asset Management Llc$3.19M0.22193,224-18.25%-$712,391.850.01
Deutsche Bank$2.94M0.2178,174+0.57%+$16,817.36<0.01
Nuveen$2.9M0.2175,7750%+$0<0.01
Simplify Asset Management Inc$2.89M0.2175,0180%+$00.28
Citigroup$2.83M0.2171,050+71.18%+$1.17M<0.01
Prudential Financial$2.8M0.19169,522New+$2.8M<0.01
Laurion Capital Management LP$2.73M0.19164,9830%+$00.02
UBS$2.71M0.19164,018+29.52%+$617,484.48<0.01
Adage Capital Partners Gp L L C$2.63M0.18159,000+6%+$148,680.000.01
Marshall Wace$2.22M0.15134,171+13.81%+$268,896.05<0.01
Bank of America$2.11M0.15127,589-20.2%-$533,513.33<0.0001
Macquarie Group$1.82M0.13110,0000%+$0<0.01
Hudson Bay Capital Management LP$1.82M0.13110,000+37.5%+$495,600.000.01
ExodusPoint Capital Management, LP$1.61M0.1197,621+138.66%+$937,156.290.02
Swiss National Bank$1.58M0.1195,4000%+$0<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.